Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 1
2005 1
2007 1
2008 4
2009 2
2010 4
2011 1
2013 3
2014 4
2015 6
2016 13
2017 4
2018 11
2019 7
2020 7
2021 8
2022 9
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
Roehlen N, Muller M, Nehme Z, Crouchet E, Jühling F, Del Zompo F, Cherradi S, Duong FHT, Almeida N, Saviano A, Fernández-Vaquero M, Riedl T, El Saghire H, Durand SC, Ponsolles C, Oudot MA, Martin R, Brignon N, Felli E, Pessaux P, Lallement A, Davidson I, Bandiera S, Thumann C, Marchand P, Moll S, Nicolay B, Bardeesy N, Hoshida Y, Heikenwälder M, Iacone R, Toso A, Meyer M, Elson G, Schweighoffer T, Teixeira G, Zeisel MB, Laquerriere P, Lupberger J, Schuster C, Mailly L, Baumert TF. Roehlen N, et al. Among authors: schuster c. J Hepatol. 2023 Feb;78(2):343-355. doi: 10.1016/j.jhep.2022.10.011. Epub 2022 Oct 27. J Hepatol. 2023. PMID: 36309131 Free article.
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.
Roehlen N, Saviano A, El Saghire H, Crouchet E, Nehme Z, Del Zompo F, Jühling F, Oudot MA, Durand SC, Duong FHT, Cherradi S, Gonzalez Motos V, Almeida N, Ponsolles C, Heydmann L, Ostyn T, Lallement A, Pessaux P, Felli E, Cavalli A, Sgrignani J, Thumann C, Koutsopoulos O, Fuchs BC, Hoshida Y, Hofmann M, Vyberg M, Viuff BM, Galsgaard ED, Elson G, Toso A, Meyer M, Iacone R, Schweighoffer T, Teixeira G, Moll S, De Vito C, Roskams T, Davidson I, Heide D, Heikenwälder M, Zeisel MB, Lupberger J, Mailly L, Schuster C, Baumert TF. Roehlen N, et al. Among authors: schuster c. Sci Transl Med. 2022 Dec 21;14(676):eabj4221. doi: 10.1126/scitranslmed.abj4221. Epub 2022 Dec 21. Sci Transl Med. 2022. PMID: 36542691
La Société de Biologie de Strasbourg : 100 ans au service de la science et de la société.
Antony P, Fournel S, Zoll J, Mantz JM, Befort K, Massotte D, Giégé P, Céraline J, Metzger D, Becker H, Drouard L, Florentz C, Martin R, Nébigil C, Potier S, Schaefer A, Schaeffer E, Schuster C, Bresson A, Quéméneur E, Choulier L, Matt N, Monassier L, Lugnier C, Freysz L, Hoffmann J, Dreyfus H, Romier C. Antony P, et al. Among authors: schuster c. Biol Aujourdhui. 2020;214(3-4):137-148. doi: 10.1051/jbio/2020018. Epub 2020 Dec 24. Biol Aujourdhui. 2020. PMID: 33357372 French.
Reply.
Verrier ER, Schuster C, Baumert TF. Verrier ER, et al. Among authors: schuster c. Hepatology. 2019 Aug;70(2):766. doi: 10.1002/hep.30663. Hepatology. 2019. PMID: 30991445 No abstract available.
Advancing hepatitis B virus entry inhibitors.
Verrier ER, Schuster C, Baumert TF. Verrier ER, et al. Among authors: schuster c. J Hepatol. 2017 Apr;66(4):677-679. doi: 10.1016/j.jhep.2016.11.028. Epub 2016 Dec 10. J Hepatol. 2017. PMID: 27965159 Free PMC article. No abstract available.
JAK1 promotes HDV replication and is a potential target for antiviral therapy.
Heuschkel MJ, Bach C, Meiss-Heydmann L, Gerges E, Felli E, Giannone F, Pessaux P, Schuster C, Lucifora J, Baumert TF, Verrier ER. Heuschkel MJ, et al. Among authors: schuster c. J Hepatol. 2024 Feb;80(2):220-231. doi: 10.1016/j.jhep.2023.10.030. Epub 2023 Nov 2. J Hepatol. 2024. PMID: 37925078 Free article.
A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery.
Crouchet E, Bandiera S, Fujiwara N, Li S, El Saghire H, Fernández-Vaquero M, Riedl T, Sun X, Hirschfield H, Jühling F, Zhu S, Roehlen N, Ponsolles C, Heydmann L, Saviano A, Qian T, Venkatesh A, Lupberger J, Verrier ER, Sojoodi M, Oudot MA, Duong FHT, Masia R, Wei L, Thumann C, Durand SC, González-Motos V, Heide D, Hetzer J, Nakagawa S, Ono A, Song WM, Higashi T, Sanchez R, Kim RS, Bian CB, Kiani K, Croonenborghs T, Subramanian A, Chung RT, Straub BK, Schuppan D, Ankavay M, Cocquerel L, Schaeffer E, Goossens N, Koh AP, Mahajan M, Nair VD, Gunasekaran G, Schwartz ME, Bardeesy N, Shalek AK, Rozenblatt-Rosen O, Regev A, Felli E, Pessaux P, Tanabe KK, Heikenwälder M, Schuster C, Pochet N, Zeisel MB, Fuchs BC, Hoshida Y, Baumert TF. Crouchet E, et al. Among authors: schuster c. Nat Commun. 2021 Sep 17;12(1):5525. doi: 10.1038/s41467-021-25468-9. Nat Commun. 2021. PMID: 34535664 Free PMC article.
87 results